Euromed AG

euro adhoc: Euromed AG
Quarterly or Semiannual Financial Statements
EUROMED AG Announces Financial Data for the First Half of 2002 (E)

--------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------- Fürth, July 23, 2002. EUROMED AG (WKN 570680), operators of a private high performance clinic and consultant in the field of quality management, finished the 2nd quarter with consolidated earnings of 10,075,000, or approximately 2.5% below the comparable period for the previous year. The consolidated pre-tax earnings (EBT) retreated to -373,000 (same period last year: +573,000). Cost savings are proceeding as planned. It was entirely due to the expansion work that space costs had an overall negative effect on the cost situation. Despite the sales and returns development to date, the company’s liquid assets increased from 444,000 to 1,003,000 during the reporting period and based on the valuation date. In the EuromedClinic business area, EUROMED AG continues to concentrate its efforts on the dispute with the Association of Private Health Insurers regarding the appropriate clinical rates. Based on the difficult market conditions overall and the development during the first half of 2002, it can be assumed that the figures for the fiscal year with regard to sales and returns will be below previous year values. end of announcement euro adhoc 23.07.2002 --------------------------------------------------------------------- Further inquiry note: Harald Niebler, Investor Relations, EUROMED AG, www.euromed.de Tel: (+49) 911 / 9714-604, Fax: (+49) 911 / 9714-607, e-mail: boerse@euromed.de Branche: Healthcare Providers ISIN: DE0005706808 WKN: 570680 Börsen: Frankfurter Wertpapierbörse / regulated dealing

Das könnte Sie auch interessieren: